Theriva Biologics, INC 8-K filings

Theriva Biologics announced second quarter 2026 financial results and provided updates on its VCN-01 clinical programs, including patient dosing in the VIRAGE2 Phase 2a study for metastatic pancreatic cancer.

Theriva Biologics has dosed the first patient in its VIRAGE2 Phase 2a clinical trial, evaluating a more frequent dosing regimen for its VCN-01 therapy in metastatic pancreatic cancer.

Theriva Biologics, Inc. announced that its stockholders approved amendments to the 2020 Stock Incentive Plan and an increase in authorized shares at the 2026 Annual Meeting.

Theriva Biologics has received regulatory approval to begin its VIRAGE2 Phase 2a clinical trial evaluating a more frequent dosing regimen of its VCN-01 therapy in combination with standard chemotherapy for metastatic pancreatic cancer.

Theriva Biologics announced publication of Phase 1 VCN-01 trial results in Head & Neck Squamous Cell Carcinoma, showing potential for immune-refractory patients.

Theriva Biologics, Inc. adjourned its June 5, 2026, special meeting due to a lack of a quorum required to approve warrant exercise proposals.

Theriva Biologics reported Q1 2026 results, highlighting FDA alignment on a Phase 3 trial for VCN-01 in metastatic pancreatic cancer and progress in retinoblastoma treatment.

Theriva Biologics announced positive subgroup analysis from its Phase 2b VIRAGE trial of VCN-01 in metastatic pancreatic cancer.

Theriva Biologics announced FDA agreement on the design of its pivotal Phase 3 clinical trial for VCN-01 in metastatic pancreatic adenocarcinoma, following successful Phase 2 results.

Theriva Biologics reported full-year 2025 financial results, highlighting progress in its VCN-01 oncology program and the licensing of SYN-020, extending its cash runway into Q1 2027.

Theriva Biologics, Inc. was unable to convene its Special Meeting of Stockholders due to a lack of quorum, necessitating a new meeting to seek approval for warrant-related share issuance.

Theriva Biologics, Inc. presented updated clinical data for its lead oncolytic virus candidate, VCN-01, showing promising results in metastatic pancreatic cancer and retinoblastoma.

Theriva Biologics received positive scientific advice from the European Medicines Agency on the design of its pivotal Phase 3 clinical trial for VCN-01 in metastatic pancreatic cancer.

Theriva Biologics, Inc. was unable to convene its Special Meeting of Stockholders due to a lack of quorum, delaying a vote on warrant exercise approval.

Theriva Biologics announced its third quarter 2025 financial results and provided updates on its oncology pipeline, including positive VCN-01 data and an extended cash runway.

Theriva Biologics, Inc. announced an at-the-market offering to sell up to $2.9 million of common stock through A.G.P./Alliance Global Partners.

Theriva Biologics, Inc. announced an at-the-market offering to sell up to $4,019,597 of common stock through A.G.P./Alliance Global Partners.

Theriva Biologics announced positive Phase 2b VIRAGE trial results for VCN-01 in metastatic pancreatic cancer, showing significant improvements in overall survival and progression-free survival.

Theriva Biologics secured approximately $4.4 million in gross proceeds by inducing existing warrant holders to exercise their warrants at a reduced price, issuing new warrants in a private placement.

Theriva Biologics announced positive expanded Phase 2b VIRAGE trial data for VCN-01 in metastatic pancreatic cancer and upcoming presentations at medical conferences.

Theriva Biologics presented preclinical data for its next-generation oncolytic adenovirus, VCN-12, showing enhanced tumor cell killing and immune response compared to VCN-01.

Theriva Biologics announced preclinical data for VCN-12 and VCN-01, highlighting advancements in oncolytic adenovirus therapies for cancer.

Theriva Biologics, Inc. announced a strategic restructuring plan, including a 32% workforce reduction, to focus resources on VCN-01 clinical trials and extend its cash runway.

Theriva Biologics stockholders approved an increase in the 2020 Stock Incentive Plan shares and elected four directors at the 2025 Annual Meeting.

Theriva Biologics announced positive topline results from its VIRAGE Phase 2b study of VCN-01 in metastatic pancreatic cancer, achieving primary survival and safety endpoints.

Theriva Biologics, Inc. has announced August 29, 2025, as the date for its 2025 Annual General Meeting of Shareholders, leading to revised deadlines for stockholder proposals and director nominations.

Theriva Biologics, Inc. has filed a prospectus supplement to offer and sell up to $2,534,352 of its common stock through an at-the-market offering facility.

Theriva Biologics announced positive Phase 1 clinical trial results for its oncolytic virus VCN-01 in refractory retinoblastoma patients, demonstrating good tolerability and promising antitumor activity, including eye preservation.

Theriva Biologics announces positive results from its Phase 2b clinical trial of VCN-01 in pancreatic cancer and the closing of a $7.5 million public offering.

Theriva Biologics successfully closed a $7.5 million public offering to support working capital, research and development, and manufacturing scale-up.